TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study

Autor: Wim J. E. Tissing, J Kruseova, A E Hoetink, G Calaminus, R Haupt, I K Domingo, E van Dulmen-den Broeder, Amit P. Bhavsar, J Byrne, H Hasle, C Spix, S Elsner, A P Nagtegaal, L Kenborg, J Gebauer, O Zolk, S M F Pluijm, A J M Meijer, H Binder, R A Ozinga, C Rechnitzer, S J C M M Neggers, M L Garrè, P Matulat, D Deuster, T Langer, Britt I. Drögemöller, H. J. H. van der Pal, D Grabow, Leontien C. M. Kremer, Galen E.B. Wright, E Clemens, A.L.F. van der Kooi, M Kaiser, Bruce Carleton, F A Diepstraten, J F Winther, C Blattmann, L Broer, M van Grotel, R Parfitt, A G Am Zehnhoff-Dinnesen, K Kepakova, H Lackner, M M van den Heuvel-Eibrink, Shahrad Rod Rassekh, T Kepak, A. C. H. de Vries, Beth Brooks, André G. Uitterlinden, C. E. Kuehni, A Tillmanns, Wilbert P. Vermeij, Colin J. D. Ross, P Kaatsch
Přispěvatelé: Pediatric surgery, CCA - Cancer Treatment and quality of life, Amsterdam Reproduction & Development (AR&D), CCA - Cancer biology and immunology, Internal Medicine, Pediatrics, Obstetrics & Gynecology, Otorhinolaryngology and Head and Neck Surgery, Guided Treatment in Optimal Selected Cancer Patients (GUTS)
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: 37. Wissenschaftliche Jahrestagung der Deutschen Gesellschaft für Phoniatrie und Pädaudiologie (DGPP); 20210917-20210918; sine loco [digital]; DOCP15 /20211028/
The PanCareLIFE Consortium & and the CPNDS Consortium 2021, ' TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study ', npj Precision Oncology, vol. 5, no. 1, 64 . https://doi.org/10.1038/s41698-021-00178-z
Meijer, A J M, Diepstraten, F A, Langer, T, Broer, L, Domingo, I K, Clemens, E, Uitterlinden, A G, de Vries, A C H, van Grotel, M, Vermeij, W P, Ozinga, R A, Binder, H, Byrne, J, van Dulmen-den Broeder, E, Garrè, M L, Grabow, D, Kaatsch, P, Kaiser, M, Kenborg, L, Winther, J F, Rechnitzer, C, Hasle, H, Kepak, T, Kepakova, K, Tissing, W J E, van der Kooi, A L F, Kremer, L C M, Kruseova, J, Pluijm, S M F, Kuehni, C E, van der Pal, H J H, Parfitt, R, Spix, C, Tillmanns, A, Deuster, D, Matulat, P, Calaminus, G, Hoetink, A E, Elsner, S, Gebauer, J, Haupt, R, Lackner, H, Blattmann, C, Neggers, S J C M M, Rassekh, S R, Wright, G E B, Brooks, B, Nagtegaal, A P, Drögemöller, B I, Ross, C J D, The PanCareLIFE consortium & and the CPNDS Consortium 2021, ' TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study ', npj Precision Oncology, vol. 5, no. 1, 64 . https://doi.org/10.1038/s41698-021-00178-z
Meijer, A J M, Diepstraten, F A, Langer, T, Broer, L, Domingo, I K, Clemens, E, Uitterlinden, A G, de Vries, A C H, van Grotel, M, Vermeij, W P, Ozinga, R A, Binder, H, Byrne, J, van Dulmen-den Broeder, E, Garrè, M L, Grabow, D, Kaatsch, P, Kaiser, M, Kenborg, L, Winther, J F, Rechnitzer, C, Hasle, H, Kepak, T, Kepakova, K, Tissing, W J E, van der Kooi, A L F, Kremer, L C M, Kruseova, J, Pluijm, S M F, Kuehni, C E, van der Pal, H J H, Parfitt, R, Spix, C, Tillmanns, A, Deuster, D, Matulat, P, Calaminus, G, Hoetink, A E, Elsner, S, Gebauer, J, Haupt, R, Lackner, H, Blattmann, C, Neggers, S J C M M, Rassekh, S R, Wright, G E B, Brooks, B, Nagtegaal, A P, Drögemöller, B I, Ross, C J D, the PanCareLIFE Consortium & and the CPNDS Consortium 2021, ' TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study ', npj Precision Oncology, vol. 5, 64 . https://doi.org/10.1038/s41698-021-00178-z
npj Precision Oncology, 5(1):64. Springer Nature
Meijer, A J M; Diepstraten, F A; Langer, T; Broer, L; Domingo, I K; Clemens, E; Uitterlinden, A G; de Vries, A C H; van Grotel, M; Vermeij, W P; Ozinga, R A; Binder, H; Byrne, J; van Dulmen-den Broeder, E; Garrè, M L; Grabow, D; Kaatsch, P; Kaiser, M; Kenborg, L; Winther, J F; ... (2021). TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. NPJ precision oncology, 5(1), p. 64. Springer Nature 10.1038/s41698-021-00178-z
NPJ Precision Oncology
NPJ precision oncology, 5(1):64, 1-8. Nature Research
npj Precision Oncology, Vol 5, Iss 1, Pp 1-8 (2021)
ISSN: 2397-768X
DOI: 10.1038/s41698-021-00178-z
Popis: Background: Ototoxicity (hearing loss, tinnitus and/or vertigo) is a serious adverse event of cisplatin treatment in children with cancer. The heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. This study investigated the association between carriership of novel single nucleotide polymorphisms (SNPs) and cisplatin-induced hearing loss (CIHL) in childhood cancer patients.Material and methods: The discovery cohort included cisplatin treated, non-cranial irradiated pediatric cancer patients within the European PanCareLIFE (PCL) study (N=390). CIHL at end of cancer treatment was defined as Muenster grade >=2b, assessed by pure tone audiometry. DNA was genotyped using the Infinium© Global Screening Array. Logistic regression models were applied including age at diagnosis, sex, cisplatin total cumulative dose and principal components 1-4, assuming an additive effect of the minor allele. Replication of the findings was performed in two independent, similarly treated cohorts (N=192 and N=188). Functional validation experiments in cultured human HeLa cell lines were performed to determine the effect of knockdown of the SNPs nearest identified gene on cisplatin-induced toxicity.Results: In the PCL discovery cohort, 8 SNPs reached a suggestive significance of P
Databáze: OpenAIRE
Externí odkaz: